Literature DB >> 29556925

Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Cédric Rossi1,2, Marie-Lorraine Chrétien3,4, René-Olivier Casasnovas5,6.   

Abstract

Antibody-drug conjugates (ADCs) are an emerging class of therapeutic agents that bring new opportunities for the treatment of hematological malignancies by meeting unmet medical needs. These drugs consist of a cytotoxic agent connected by a linker to a human, humanized, or chimeric antibody targeting a surface antigen specifically expressed by tumor cells. These ADCs are being developed to specifically deliver the cytotoxic agent into tumor cells. The cytotoxic payload is released from the ADC after internalization and cleavage of the linker, ultimately triggering the death of the cancer cell. Second- and even third-generation ADCs are currently being developed and have more stable linkers and more potent payloads, which should improve ADC efficacy even further. In this review, we analyze the results for the main ADCs currently developed and discuss the advantages and drawbacks of this therapeutic option.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29556925     DOI： 10.1007/s11523-018-0558-1

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


  159 in total

Review 1.  CD27 and CD70 in T cell and B cell activation.

Authors:  Jannie Borst; Jenny Hendriks; Yanling Xiao
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

2.  Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Authors:  Maria Corinna A Palanca-Wessels; Myron Czuczman; Gilles Salles; Sarit Assouline; Laurie H Sehn; Ian Flinn; Manish R Patel; Randeep Sangha; Anton Hagenbeek; Ranjana Advani; Herve Tilly; Olivier Casasnovas; Oliver W Press; Sreeni Yalamanchili; Robert Kahn; Randall C Dere; Dan Lu; Surai Jones; Cheryl Jones; Yu-Waye Chu; Franck Morschhauser
Journal:  Lancet Oncol       Date:  2015-04-27       Impact factor: 41.316

3.  cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure.

Authors:  L Claesson; D Larhammar; L Rask; P A Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

4.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Authors:  Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jorge Cortes; Luis Fayad; Robert Tarnai; Sa A Wang; Richard Champlin; Anjali Advani; Susan O'Brien
Journal:  Lancet Oncol       Date:  2012-02-21       Impact factor: 41.316

5.  The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival.

Authors:  Annemiek B van Spriel; Sandra de Keijzer; Alie van der Schaaf; Kate H Gartlan; Mariam Sofi; Amanda Light; Peter C Linssen; Jan B Boezeman; Malou Zuidscherwoude; Inge Reinieren-Beeren; Alessandra Cambi; Fabienne Mackay; David M Tarlinton; Carl G Figdor; Mark D Wright
Journal:  Sci Signal       Date:  2012-11-13       Impact factor: 8.192

6.  Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival.

Authors:  Diana Starlets; Yael Gore; Inbal Binsky; Michal Haran; Nurit Harpaz; Lev Shvidel; Shirly Becker-Herman; Alain Berrebi; Idit Shachar
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

7.  Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.

Authors:  David Dornan; Fiona Bennett; Yvonne Chen; Mark Dennis; Dan Eaton; Kristi Elkins; Dorothy French; Mary Ann T Go; Andrew Jack; Jagath R Junutula; Hartmut Koeppen; Jeffrey Lau; Jacqueline McBride; Andy Rawstron; Xiaoyan Shi; Nancy Yu; Shang-Fan Yu; Peng Yue; Bing Zheng; Allen Ebens; Andrew G Polson
Journal:  Blood       Date:  2009-07-24       Impact factor: 22.113

Review 8.  Targeting B-cell maturation antigen in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Immunotherapy       Date:  2015-09-15       Impact factor: 4.196

9.  A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.

Authors:  U Brinkmann; Y Reiter; S H Jung; B Lee; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 12.779

10.  The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.

Authors:  K A Beckwith; F W Frissora; M R Stefanovski; W H Towns; C Cheney; X Mo; J Deckert; C M Croce; J M Flynn; L A Andritsos; J A Jones; K J Maddocks; G Lozanski; J C Byrd; N Muthusamy
Journal:  Leukemia       Date:  2014-01-21       Impact factor: 11.528
View more
  1 in total

Review 1.  Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.

Authors:  A R Kumar; M Murali; B Nair; K Pavithran; A R Devan; G K Pradeep; L R Nath
Journal:  Clin Transl Oncol       Date:  2021-09-30       Impact factor: 3.405
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.